Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of KPG-121 in Combination With Enzalutamide in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Trial Profile

Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of KPG-121 in Combination With Enzalutamide in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs Enzalutamide (Primary) ; KPG-121 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Kangpu Biopharmaceuticals
  • Most Recent Events

    • 15 Oct 2018 Planned End Date changed from 1 May 2020 to 1 Jun 2020.
    • 15 Oct 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Oct 2019.
    • 29 Aug 2018 Planned number of patients changed from 24 to 36.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top